TheraRadar
Data updated: May 26, 2026

BONIVA (ibandronate sodium)

Musculoskeletal Approved 2003-05-16
Jump to: Indications Approvals Trials Competitors Safety Patents
4
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Discontinued
First Approved
2003-05-16
Routes
INTRAVENOUS, ORAL
Dosage Forms
INJECTABLE, TABLET

Companies

Roche
Active Ingredient: IBANDRONATE SODIUM

BONIVA Approval History

2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
50 FDA actions from 2003 to 2022 · 2 indication expansions
Jan 2022 SUPPL
Label · Labeling
FDA Letter Label
Dec 2016 SUPPL
Label · Labeling
FDA Letter Label
Jul 2015 SUPPL
Mfg · Manufacturing (CMC)

What BONIVA Treats

4 FDA approvals

Originally approved for its first indication in 2003 . Covers 4 distinct patient populations.

  • Other (4)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01627886 BA0859144-01 Ph 1 completed Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BONIVA FDA Label Details

Track BONIVA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA021858 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.